Kawagoe, Japan

Mamoru Yokoo



Average Co-Inventor Count = 6.6

ph-index = 5

Forward Citations = 80(Granted Patents)


Location History:

  • Kawagoe, JP (1986 - 1994)
  • Kyoto, JP (1997 - 1999)
  • Otsu, JP (2007)

Company Filing History:


Years Active: 1986-2007

Loading Chart...
Loading Chart...
10 patents (USPTO):

Title: Mamoru Yokoo: Innovator in Antimicrobial Treatments

Introduction

Mamoru Yokoo is a distinguished inventor based in Kawagoe, Japan. He has made significant contributions to the field of antimicrobial treatments, holding a total of 10 patents. His innovative approaches have paved the way for advancements in medical therapies, particularly in the treatment of onychomycosis.

Latest Patents

Among his latest patents is a method for treating onychomycosis. This novel method evaluates the effect of an antimicrobial agent by removing any remaining agent in a biological sample. This allows for an accurate assessment of the antimicrobial agent's effectiveness without interference from residual substances. Another notable patent is for a therapeutic agent for onychomycosis, which can be obtained through the aforementioned evaluation method. Additionally, he has developed an azolylamine derivative, which is a fungicide containing a compound with a specific general formula. This compound is particularly effective when it has an R,R-configuration.

Career Highlights

Mamoru Yokoo is currently associated with Kaken Pharmaceutical Company, Ltd., where he continues to innovate in the field of pharmaceuticals. His work has been instrumental in developing effective treatments for fungal infections, showcasing his commitment to improving patient outcomes.

Collaborations

He has collaborated with notable coworkers, including Tadashi Arika and Kouji Amemiya, who have contributed to his research and development efforts.

Conclusion

Mamoru Yokoo's contributions to antimicrobial treatments highlight his role as a leading inventor in the pharmaceutical industry. His innovative patents and ongoing work at Kaken Pharmaceutical Company, Ltd. continue to impact the field positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…